<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03450005</url>
  </required_header>
  <id_info>
    <org_study_id>Candi001</org_study_id>
    <nct_id>NCT03450005</nct_id>
  </id_info>
  <brief_title>ECMM Candida Registry - CandiReg</brief_title>
  <acronym>CandiReg</acronym>
  <official_title>ECMM Candida Registry - CandiReg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the European Confederation of Medical Mycology - ECMM Candida Registry
      (CandiReg) is to overcome the lack of knowledge on epidemiology, clinical course, and
      molecular characteristics of invasive infections due to invasive Candida infections and to
      function as a platform for future studies and in case of outbreaks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific objectives are:

      To describe the global incidence of invasive Candida infection To monitor trends globally and
      locally over time To define patient risk groups To assess antifungal resistance among Candida
      spp. causing invasive diseases worldwide To assess attributable mortality of invasive Candida
      infection To assess incremental costs associated with invasive Candida infection

      To describe the clinical pattern of disease To document diagnostic procedures performed for
      confirmation of diagnosis To describe first-line and salvage treatment regimens applied,
      guideline adherence, their efficacy and impact on patient survival To inform consensus
      guidelines To develop clinical screening and diagnostic procedures

      Set up of a collection of isolates with molecular characterization and evaluation of
      resistance genes
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2018</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence</measure>
    <time_frame>up to 100 weeks</time_frame>
    <description>To describe the global incidence of invasive Candida infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>up to 100 weeks</time_frame>
    <description>To describe the global mortality of invasive Candida infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Molecular characteristics of Candida auris</measure>
    <time_frame>At 90 Days from diagnosis</time_frame>
    <description>To describe the molecular characteristics of Candida auris</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Susceptibility testing</measure>
    <time_frame>At 90 Days from diagnosis</time_frame>
    <description>To describe the susceptibility of Candida auris</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resistance development</measure>
    <time_frame>up to 100 weeks</time_frame>
    <description>To describe the resistance development of Candida auris</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment efficacy of invasive candida infections</measure>
    <time_frame>At 90 Days from diagnosis</time_frame>
    <description>Number of participants with treatment failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment efficacy of invasive candida infections</measure>
    <time_frame>At 90 Days from diagnosis</time_frame>
    <description>Number of participants with stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment efficacy of invasive candida infections</measure>
    <time_frame>At 90 Days from diagnosis</time_frame>
    <description>Number of participants with partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment efficacy of invasive candida infections</measure>
    <time_frame>At 90 Days from diagnosis</time_frame>
    <description>Number of participants with complete response</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Invasive Candidiases</condition>
  <arm_group>
    <arm_group_label>emerging Candida isolates</arm_group_label>
    <description>Web-based registry of invasive infections by Candida species</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      fungal culture
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Invasive infections caused by Candida species
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cultural, histopathological, antigen or DNA evidence of invasive fungal infection with
             Candida species.

          -  Hepatosplenic candidiasis with signs of disseminated Candida infection without
             culture, histological or microscopic evidence

          -  Case control

        Matching procedure for controls:

        In part, controls will be included at the same hospitals that include cases (i.e. each one
        control per case, both in the same hospital).

        Controls will be matched by demographics, underlying diseases and risk factors as well as
        duration of hospitalization

        Exclusion Criteria:

        - Colonization or other non-invasive infection, including superficial skin infections,
        candiduria without dissemination or Candida spp. in stool.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Cornely, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Cologne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oliver Cornely, MD</last_name>
    <phone>+49 221 478</phone>
    <phone_ext>85223</phone_ext>
    <email>oliver.cornely@uk-koeln.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Cornely, MD</last_name>
      <phone>+49 221 478</phone>
      <phone_ext>85523</phone_ext>
      <email>oliver.cornely@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Philipp Koehler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2018</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Oliver Cornely, MD</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Invasive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

